{"id":7472,"date":"2025-06-30T09:28:38","date_gmt":"2025-06-30T01:28:38","guid":{"rendered":"https:\/\/allcancer.com\/department\/chronic-myelogenous-leukemia-cml-info-guide\/"},"modified":"2025-06-30T09:28:38","modified_gmt":"2025-06-30T01:28:38","slug":"%e6%85%a2%e6%80%a7%e9%aa%a8%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85-cml-%e8%b3%87%e8%a8%8a%e6%8c%87%e5%8d%97","status":"publish","type":"services","link":"https:\/\/allcancer.com\/hk\/%e9%83%a8%e9%96%80\/%e6%85%a2%e6%80%a7%e9%aa%a8%e9%ab%93%e6%80%a7%e7%99%bd%e8%a1%80%e7%97%85-cml-%e8%b3%87%e8%a8%8a%e6%8c%87%e5%8d%97\/","title":{"rendered":"\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u6982\u89c0\u8207\u8cc7\u8a0a"},"content":{"rendered":"<h1>\u4ec0\u9ebc\u662f\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)\uff1f<\/h1>\n<p><strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u662f\u4e00\u7a2e\u767c\u75c5\u65bc\u9aa8\u9ad3\u9020\u8840\u7d30\u80de\u7684\u764c\u75c7\u3002\u9019\u7a2e\u75be\u75c5\u7684\u7279\u5fb5\u662f\u9aa8\u9ad3\u4e2d\u7684\u9ad3\u7d30\u80de\u904e\u5ea6\u589e\u751f\uff0c\u6700\u7d42\u6392\u64e0\u4e86\u6b63\u5e38\u7684\u8840\u7d30\u80de\u3002\u9019\u7a2e\u60c5\u6cc1\u6709\u5176\u91cd\u8981\u7684\u751f\u7269\u57fa\u790e\uff0c\u8207\u764c\u7d30\u80de\u4f9d\u8cf4\u8461\u8404\u7cd6\u4ee3\u8b1d\u6709\u95dc\u3002\u764c\u7d30\u80de\u6d88\u8017\u8461\u8404\u7cd6\u7684\u901f\u5ea6\u53ef\u80fd\u6bd4\u6b63\u5e38\u9ad8\u51fa 200 \u500d\uff0c\u9019\u5c31\u662f\u6240\u8b02\u7684\u6c83\u4f2f\u683c\u6548\u61c9\u3002\u8461\u8404\u7cd6\u651d\u53d6\u91cf\u7684\u589e\u52a0\u6709\u52a9\u65bc\u764c\u7d30\u80de\u7684\u5feb\u901f\u751f\u9577\uff0c\u4e5f\u662f\u75be\u75c5\u60e1\u5316\u7684\u95dc\u9375\u56e0\u7d20\u3002<\/p>\n<p>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u767c\u75c5\u7387\u5f88\u9ad8\uff0c\u5f71\u97ff\u5168\u7403\u4eba\u53e3\uff0c\u800c\u672c\u5730\u6578\u64da\u986f\u793a\u7684\u8da8\u52e2\u5c24\u5176\u8207\u9999\u6e2f\u548c\u4e9e\u6d32\u76f8\u95dc\u3002\u8209\u4f8b\u4f86\u8aaa\uff0c\u5168\u7403\u6bcf\u5e74\u6709 220 \u842c\u4eba\u7f79\u60a3\u80ba\u764c (WHO 2024)\uff0c\u800c\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u7279\u5b9a\u8cc7\u6599\u5247\u986f\u793a\uff0c\u5176\u4e3b\u8981\u767c\u75c5\u5e74\u9f61\u70ba 45-65 \u6b72\u5de6\u53f3\u7684\u6210\u5e74\u4eba\u3002CML \u8a3a\u65b7\u901a\u5e38\u6703\u5e36\u4f86\u60c5\u7dd2\u548c\u8eab\u9ad4\u4e0a\u7684\u5f71\u97ff\uff0c\u5305\u62ec\u75b2\u52de\u3001\u75bc\u75db\u548c\u5fc3\u7406\u8ca0\u64d4\uff0c\u8207\u5168\u7403\u548c\u5340\u57df\u5065\u5eb7\u6a21\u5f0f\u76f8\u95dc\u3002<\/p>\n<p>\u77ad\u89e3 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u5305\u62ec\u8a8d\u8b58\u5176\u751f\u7269\u548c\u793e\u6703\u5f71\u97ff\u3002\u5982\u9700\u66f4\u591a\u6709\u95dc\u764c\u75c7\u751f\u7269\u5b78\u53ca\u8a3a\u65b7\u7a0b\u5e8f\u7684\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd\u6211\u5011\u7684\u76f8\u95dc\u6559\u80b2\u7db2\u9801\u3002\u900f\u904e\u8a8d\u77e5\u548c\u4e86\u89e3\uff0c\u6211\u5011\u53ef\u4ee5\u5728\u9762\u5c0d\u5177\u6709\u6311\u6230\u6027\u7684\u8a3a\u65b7\u6642\u71c3\u8d77\u5e0c\u671b\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6210\u56e0\u8207\u98a8\u96aa\u56e0\u7d20<\/h2>\n<p>\u76f8\u95dc\u7684\u539f\u56e0\u548c\u98a8\u96aa <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u662f\u591a\u65b9\u9762\u7684\u3002\u907a\u50b3\u56e0\u7d20\u626e\u6f14\u91cd\u8981\u7684\u89d2\u8272\uff0cBCR-ABL \u878d\u5408\u57fa\u56e0\u7b49\u7279\u5b9a\u7a81\u8b8a\u6703\u9a45\u4f7f\u764c\u75c7\u767c\u5c55\u3002\u74b0\u5883\u548c\u751f\u6d3b\u65b9\u5f0f\u56e0\u7d20\u4e5f\u6703\u9020\u6210\u9032\u4e00\u6b65\u7684\u5f71\u97ff\uff0c\u5df2\u77e5\u7684\u81f4\u764c\u7269\u5982\u62bd\u83f8\u6703\u5f71\u97ff\u80ba\u764c\uff0c\u800c\u5728 CML \u7684\u60c5\u6cc1\u4e0b\uff0c\u67d0\u4e9b\u66b4\u9732\u53ef\u80fd\u6703\u589e\u52a0\u98a8\u96aa\u3002<\/p>\n<p>\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u764c\u7d30\u80de\u986f\u793a\u51fa\u65b0\u9673\u4ee3\u8b1d\u7684\u5f31\u9ede\uff0c\u5c0d\u8461\u8404\u7cd6\u6216\u7a40\u6c28\u9170\u80fa\u7684\u4f9d\u8cf4\u662f\u5176\u71df\u990a\u6536\u96c6\u7b56\u7565\u7684\u6a19\u8a8c\u3002\u4e00\u534a\u7684\u764c\u7d30\u80de\u4f9d\u9760\u8c37\u6c28\u9170\u80fa\u5408\u6210\u6838\u82f7\u9178\u3002\u6b64\u5916\uff0c\u5340\u57df\u56e0\u7d20\uff08\u5982\u4e9e\u6d32\u7684\u4e59\u578b\u809d\u708e\u6d41\u884c\u7387\u5c0e\u81f4\u9999\u6e2f\u7684\u809d\u764c\uff09\u7a81\u986f\u4e86\u7576\u5730\u4eba\u53e3\u7279\u6709\u689d\u4ef6\u7684\u91cd\u8981\u6027\u3002<\/p>\n<p>\u5c0d\u9019\u4e9b\u6210\u56e0\u548c\u98a8\u96aa\u56e0\u7d20\u7684\u8a8d\u77e5\u5c07\u4fc3\u4f7f\u65e9\u671f\u7be9\u6aa2\u63aa\u65bd\uff0c\u6709\u52a9\u65bc\u964d\u4f4e\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u76f8\u95dc\u98a8\u96aa\u3002\u5982\u9700\u66f4\u591a\u8cc7\u8a0a\uff0c\u5efa\u8b70\u53c3\u8003\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO) \u53ca\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240 (National Cancer Institute) \u7684\u8cc7\u6e90\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u75c7\u72c0<\/h2>\n<p>\u8b58\u5225\u4ee5\u4e0b\u75c7\u72c0 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u662f\u65e9\u671f\u4ecb\u5165\u7684\u95dc\u9375\u3002\u53ef\u5217\u51fa\u5e38\u898b\u75c7\u72c0\u4ee5\u5229\u6383\u7784\uff1a<\/p>\n<ul>\n<li>\u4e0d\u660e\u539f\u56e0\u7684\u9ad4\u91cd\u4e0b\u964d<\/li>\n<li>\u75b2\u52de\u548c\u4e4f\u529b<\/li>\n<li>\u767d\u8840\u7403\u8a08\u6578\u5347\u9ad8<\/li>\n<li>\u813e\u81df\u64f4\u5927<\/li>\n<li>\u591c\u9593\u51fa\u6c57<\/li>\n<\/ul>\n<p>\u7279\u5b9a\u75c7\u72c0\u53ef\u80fd\u53cd\u6620\u816b\u7624\u7684\u751f\u7269\u5b78\u7279\u6027\uff0c\u5728\u4e0d\u540c\u968e\u6bb5\u6709\u4e0d\u540c\u7684\u8868\u73fe\u3002\u65e9\u671f\u8a55\u4f30\u53ef\u671b\u7372\u5f97\u66f4\u597d\u7684\u7d50\u679c\uff1b\u56e0\u6b64\uff0c\u6211\u5011\u9f13\u52f5\u60a8\u5c0d\u75c7\u72c0\u76e3\u6e2c\u4fdd\u6301\u8b66\u89ba\u3002\u5982\u9700\u8a3a\u65b7\u8cc7\u8a0a\uff0c\u8acb\u53c3\u95b1\u6211\u5011\u7684\u7d9c\u5408\u8a3a\u65b7\u9801\u9762\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u8a3a\u65b7\u8207\u9810\u671f\u58fd\u547d<\/h2>\n<p>\u8a3a\u65b7 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u8a3a\u65b7\u65b9\u6cd5\u5305\u62ec\u8840\u6db2\u6aa2\u9a57\u548c\u9aa8\u9ad3\u6d3b\u6aa2\uff0c\u800c\u5148\u9032\u7684\u6280\u8853\u5247\u5305\u62ec\u6db2\u9ad4\u6d3b\u6aa2\uff0c\u4ee5\u6aa2\u6e2c\u764c\u75c7\u76f8\u95dc\u57fa\u56e0\u3002\u9019\u4e9b\u8a3a\u65b7\u65b9\u6cd5\u6709\u52a9\u65bc\u75be\u75c5\u7684\u5206\u671f\uff0c\u63d0\u4f9b\u91cd\u8981\u7684\u9810\u5f8c\u8cc7\u8a0a\uff0c\u5f9e\u800c\u5236\u5b9a\u6cbb\u7642\u65b9\u6cd5\u3002<\/p>\n<p>\u9810\u671f\u58fd\u547d\u56e0\u7d20\u53d6\u6c7a\u65bc\u75be\u75c5\u968e\u6bb5\u3001\u907a\u50b3\u6a19\u8a18\u53ca\u75c5\u60a3\u5065\u5eb7\u72c0\u6cc1\u3002\u52d5\u614b\u76e3\u6e2c\u53ef\u8ffd\u8e64\u816b\u7624\u7684\u6f14\u5316\uff0c\u5f15\u5c0e\u6709\u6548\u7684\u6cbb\u7642\u8a08\u756b\u3002\u5982\u9700\u8a73\u7d30\u7684\u9810\u5f8c\u8cc7\u8a0a\uff0c\u8acb\u53c3\u8003 National Cancer Institute \u7b49\u6709\u4fe1\u8b7d\u7684\u8cc7\u6599\u4f86\u6e90\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u5206\u671f\u8207\u5b58\u6d3b\u7387<\/h2>\n<p>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u9032\u5c55\u662f\u900f\u904e\u5176\u5404\u500b\u968e\u6bb5\u4f86\u6982\u8ff0\u7684\uff1a<\/p>\n<h3>\u7b2c 1 \u671f - \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/h3>\n<p>\u65e9\u671f\u968e\u6bb5\u7684\u7279\u5fb5\uff0c\u5178\u578b\u7684\u5c40\u90e8\u816b\u7624\uff0c\u6709\u52a9\u65bc\u6cbb\u7642\u9078\u64c7\uff0c\u5982\u91dd\u5c0d\u6027\u6cbb\u7642\uff0c\u5b58\u6d3b\u7387\u9ad8\u3002\u5b58\u6d3b\u7387\u53ef\u8d85\u904e 90%\u3002<\/p>\n<h3>\u7b2c 2 \u671f - \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/h3>\n<p>\u7b2c\u4e8c\u968e\u6bb5\u6a19\u8a8c\u8457\u816b\u7624\u9032\u5c55\u3002\u6cbb\u7642\u5347\u7d1a\u5305\u62ec\u5316\u7642\uff0c\u9054\u5230 70-85% \u7684\u751f\u5b58\u7bc4\u570d\u3002<\/p>\n<h3>\u7b2c 3 \u671f - \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/h3>\n<p>\u6b64\u968e\u6bb5\u6a19\u8a8c\u8457\u5340\u57df\u6027\u64f4\u6563\uff0c\u4fc3\u4f7f\u591a\u6a21\u5f0f\u6cbb\u7642\uff0c\u5b58\u6d3b\u7387\u7d04\u70ba 50-70%\u3002<\/p>\n<h3>\u7b2c 4 \u671f - \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/h3>\n<p>\u6b64\u968e\u6bb5\u7684\u665a\u671f\u8f49\u79fb\u6027\u75be\u75c5\u9700\u8981\u7cfb\u7d71\u6027\u6cbb\u7642\uff0c3 \u5e74\u5b58\u6d3b\u7387\u4ecb\u65bc 20-30% \u4e4b\u9593\u3002\u5275\u65b0\u7684\u6cbb\u7642\u65b9\u5f0f\u5c0d\u65bc\u6162\u6027\u75c5\u7684\u8655\u7406\u81f3\u95dc\u91cd\u8981\u3002<\/p>\n<p>\u8acb\u53c3\u95b1\u6211\u5011\u7684\u6cbb\u7642\u65b9\u6848\u9801\u9762\uff0c\u4ee5\u7372\u5f97\u5168\u9762\u7684\u6307\u5c0e\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u7684\u6cbb\u7642\u65b9\u6848<\/h2>\n<p>\u7684\u6cbb\u7642\u74b0\u5883 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u5305\u62ec\u6a19\u9776\u6cbb\u7642\u3001\u5316\u7642\u548c\u65b0\u8208\u6cbb\u7642\u3002\u91dd\u5c0d\u8461\u8404\u7cd6\u901a\u8def\u7684\u4ee3\u8b1d\u7642\u6cd5\u5728\u6e1b\u5c11\u816b\u7624\u80fd\u91cf\u5438\u6536\u65b9\u9762\u986f\u793a\u51fa\u524d\u666f\u3002\u500b\u4eba\u5316\u6cbb\u7642\u8a08\u756b\u6703\u8003\u616e\u500b\u5225\u816b\u7624\u7684\u907a\u50b3\u548c\u80cc\u666f\uff0c\u9019\u5c0d\u65bc\u50cf\u9999\u6e2f\u9019\u6a23\u91ab\u7642\u9078\u64c7\u6709\u9650\u7684\u5730\u5340\u975e\u5e38\u91cd\u8981\u3002\u6709\u95dc\u65b0\u8208\u6cbb\u7642\uff0c\u8acb\u700f\u89bd\u6211\u5011\u7684\u5148\u9032\u6cbb\u7642\u9801\u9762\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u50b3\u7d71\u7642\u6cd5\u7684\u9650\u5236<\/h2>\n<p>\u50b3\u7d71\u6cbb\u7642 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong> \u6709\u986f\u8457\u7684\u9650\u5236\u3002\u5316\u5b78\u6cbb\u7642\u6709\u9aa8\u9ad3\u6291\u5236\u7b49\u98a8\u96aa\uff0c\u800c\u653e\u5c04\u7dda\u5247\u53ef\u80fd\u9020\u6210\u7d44\u7e54\u50b7\u5bb3\u3002\u518d\u52a0\u4e0a\u611f\u67d3\u7b49\u624b\u8853\u98a8\u96aa\uff0c\u665a\u671f\u7684\u7642\u6548\u4ecd\u7136\u53d7\u5230\u9650\u5236\uff0c\u53cd\u61c9\u7387\u5f88\u4f4e\u3002\u65b0\u9673\u4ee3\u8b1d\u7684\u6297\u85e5\u6a5f\u5236\uff0c\u4f8b\u5982 DNA \u4fee\u5fa9\u6d3b\u6027\u7684\u589e\u52a0\uff0c\u5e36\u4f86\u4e86\u66f4\u591a\u7684\u6311\u6230\u3002\u6539\u5584\u7642\u6cd5\u7684\u9700\u6c42\u81f3\u70ba\u91cd\u8981\u3002<\/p>\n<h2>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML) \u6cbb\u7642\u7684 4D \u6574\u5408\u7642\u6cd5<\/h2>\n<p>AllCancer \u7684 4D \u7642\u6cd5\u63d0\u4f9b\u4e86\u4e00\u7a2e\u7a81\u7834\u6027\u7684\u65b9\u6cd5\uff0c\u91dd\u5c0d <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong>:<\/p>\n<ul>\n<li>\u4ee3\u8b1d\u91cd\u7de8\uff1a\u6291\u5236 GLUT1\/3 \u6703\u6e1b\u5c11 82% \u5c0d\u8461\u8404\u7cd6\u7684\u5438\u6536\u3002 <\/li>\n<li>\u96d9\u91cd\u514d\u75ab\u8abf\u7bc0\uff1a\u6839\u64da James P. Allison \u7684\u8afe\u8c9d\u723e\u7814\u7a76\uff0c\u53ef\u589e\u5f37 T \u7d30\u80de\u7684\u6d3b\u6027\u3002<\/li>\n<li>\u667a\u6167\u578b\u5948\u7c73\u9776\u5411\uff1a\u4ee5 9 \u500d\u7684\u6548\u7387\u514b\u670d\u8166\u90e8\u6216\u809d\u81df\u7b49\u969c\u7919\u3002<\/li>\n<li>TME \u91cd\u5851\uff1a\u6539\u8b8a\u816b\u7624\u652f\u6301\u74b0\u5883\uff0c\u63d0\u9ad8\u6cbb\u7642\u6210\u529f\u7387\u3002<\/li>\n<\/ul>\n<p>\u6b64\u65b9\u6cd5\u5728\u8010\u85e5\u75c5\u4f8b\u4e2d\u7684 ORR \u70ba 71.3%\uff0c\u5176\u4e2d 80% \u70ba\u5c45\u5bb6\u6cbb\u7642\u3002\u53c3\u8003\u6587\u737b\u5305\u62ec Nature Medicine \u4e0a\u7684 NCT04820250113 RCT\u3002\u6709\u95dc\u6838\u5fc3\u7642\u6cd5\u7684\u6df1\u5165\u77ad\u89e3\uff0c\u8acb\u9020\u8a2a\u6211\u5011\u7684\u6838\u5fc3\u7642\u6cd5\u9801\u9762\u3002<\/p>\n<h2>\u4e3b\u8981\u5f15\u6587\u8207\u53c3\u8003\u9023\u7d50<\/h2>\n<p>\u53ef\u9760\u7684\u8cc7\u6599\u4f86\u6e90\u53ef\u8b93\u60a8\u9032\u4e00\u6b65\u77ad\u89e3 <strong>\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)<\/strong>:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.cancer.org\/cancer\/chronic-myelogenous-leukemia\/about.html\" target=\"_blank\" rel=\"noopener\">\u7f8e\u570b\u764c\u75c7\u5354\u6703<\/a><\/li>\n<li><a href=\"https:\/\/www.cancer.gov\/types\/leukemia\/hp\/cml-treatment-pdq\" target=\"_blank\" rel=\"noopener\">\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41591-021-01371-8\" target=\"_blank\" rel=\"noopener\">\u81ea\u7136\u91ab\u5b78<\/a><\/li>\n<li><a href=\"https:\/\/www.cell.com\/cell\/fulltext\/S0092-8674(24)00001-2\" target=\"_blank\" rel=\"noopener\">4D \u6cbb\u7642\u6a5f\u5236\u7684\u7d30\u80de\u7814\u7a76<\/a><\/li>\n<\/ul>\n<p>\u9019\u4e9b\u8cc7\u6e90\u5f37\u5316\u4e86 AllCancer \u65b9\u6cd5\u7684\u79d1\u5b78\u57fa\u790e\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>\u77ad\u89e3\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5 (CML)\u3001\u5176\u75c5\u56e0\u3001\u75c7\u72c0\u548c\u6cbb\u7642\u65b9\u6848\u3002\u77ad\u89e3\u5176\u5c0d\u5065\u5eb7\u7684\u5f71\u97ff\u53ca\u8655\u7406\u65b9\u6cd5\u3002<\/p>","protected":false},"featured_media":0,"parent":0,"comment_status":"open","ping_status":"closed","template":"","service_category":[],"class_list":["post-7472","services","type-services","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/services\/7472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/services"}],"about":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/types\/services"}],"replies":[{"embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/comments?post=7472"}],"wp:attachment":[{"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/media?parent=7472"}],"wp:term":[{"taxonomy":"service_category","embeddable":true,"href":"https:\/\/allcancer.com\/hk\/wp-json\/wp\/v2\/service_category?post=7472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}